MoneyWorks4Me

Dr. Reddy’s strengthens on receiving EIR from USFDA for Telangana facility

04 Dec 2017 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 2246.00, up by 15.55 points or 0.70% from its previous closing of Rs. 2230.45 on the BSE.

The scrip opened at Rs. 2277.00 and has touched a high and low of Rs. 2278.50 and Rs. 2240.00 respectively. So far 15,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3235.00 on 08-Dec-2016 and a 52 week low of Rs. 1901.65 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 2318.95 and Rs. 2222.60 respectively. The current market cap of the company is Rs. 37,243.00 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 43.15% and 15.25% respectively.

Dr. Reddy’s Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Custom Pharmaceutical Services (CPS) facility, Technology Development Centre (TDC-1) at Miyapur, Hyderabad, Telangana.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Peers
Company Name CMP
Sun Pharma. Inds. 1777.10
Dr. Reddys Labs. 1195.25
Cipla 1331.25
Lupin 2011.20
Zydus Lifesciences 1151.40
View more..